Britain gearing to start vaccine distribution before Christmas

Britain gearing to start vaccine distribution before Christmas

Governments in predominantly wealthy countries are negotiating to buy almost 8.8bn doses of prospective Covid-19 vaccines in a "frenzy of deals" that could mean many poor countries would not get access to immunisation until at least 2024, a report says.

The director in charge of COVID-19 vaccine clinical trials at Oxford University said that there are "slim chances" that the vaccine will be ready before the Christmas period Wednesday. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection.

In May, the Government promised that 30 million vaccines would be ready by September to allow for immediate mass deployment if trials were successful.

The company also reaffirmed that it expects to report data from a late-stage trial of the vaccine being conducted in Britain by the first quarter of 2021. According to the researchers, 100% of the volunteers in the clinical trials generated antibodies after two doses. The Gulf country is also taking part in clinical trials for Russia's so-called Sputnik-V vaccine. It would be manufactured in the US, Belgium and Germany.

Most of the participants have been aged 60 or over.

A committee to advise the government on the vaccine has already decided which group should be given priority for receiving the Covid-19 vaccine.

The planned global Phase 3 clinical programs will assess immunity, safety and COVID-19 disease prevention. The vaccine regimen is expected to require two doses per individual, administered 21 days apart.

Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020.

Both vaccine candidates will be made by U.S. companies.

CEPI has previously deployed vast sums of money in search of a COVID-19 vaccine through partnerships with drug developers including Inovio Pharmaceuticals Inc, Moderna Inc, and Novavax Inc.

He said that an "agreement" had been reached with general practitioners to ensure this happened, adding: "We will be writing to GP clinics this week to prepare them to start by Christmas if the vaccine becomes available".

Pfizer, which had recently said that it could have immunization viability information in October, communicated trust it could gracefully almost 40 million portions in the United States this year if clinical testing continues true to form and controllers endorse its single nucleoside-altered courier RNA (modRNA) antibody.

Meanwhile, Professor Robin Shattock, who is leading Imperial College London's Covid-19 vaccine effort, added that the world would be living with the consequences of coronavirus "for many years to come".

Related Articles